Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -132 | -62 | 27 | 89 | 178 |
| Depreciation Amortization | 21 | 11 | 41 | 31 | 21 |
| Accounts receivable | -2 | -4 | 106 | 114 | 114 |
| Accounts payable and accrued liabilities | 2 | 1 | -464 | -763 | -1,016 |
| Other Working Capital | 9 | 2 | -341 | -638 | -894 |
| Other Operating Activity | 0 | 3 | 358 | 649 | 902 |
| Operating Cash Flow | $-102 | $-49 | $-274 | $-518 | $-694 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -15 | -40 | -22 | -25 |
| Purchase Of Investment | N/A | N/A | -12 | -12 | -12 |
| Investing Cash Flow | $-9 | $-15 | $-52 | $-34 | $-37 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8 | -4 | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | 742 | 1,171 | 1,233 |
| Other Financing Activity | -1 | 0 | 2 | 0 | 5 |
| Financing Cash Flow | $-9 | $-4 | $743 | $1,171 | $1,238 |
| Exchange Rate Effect | -1 | 20 | 4 | -41 | -13 |
| Beginning Cash Position | 1,260 | 1,260 | 839 | 839 | 839 |
| End Cash Position | 1,140 | 1,213 | 1,260 | 1,416 | 1,333 |
| Net Cash Flow | $-120 | $-47 | $421 | $577 | $494 |
| Free Cash Flow | |||||
| Operating Cash Flow | -102 | -49 | -274 | -518 | -694 |
| Capital Expenditure | -9 | -15 | -40 | -22 | -25 |
| Free Cash Flow | -111 | -63 | -314 | -540 | -719 |